About: Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort
Creator	Carannante, Novella Cardillo, Giuseppe Imparato, Michele Lodigiani, Corrado Micco, Pierpaolo Rodolfi, Stefano Russo, Vincenzo
source	Medline; PMC
abstract	Introduction: A novel highly pathogenic human coronavirus able to induce severe acute respiratory syndrome (SARS) has been recently recognized as the cause of the coronavirus disease 2019 (COVID-19) outbreak, which has spread rapidly from China to other countries. Little is known about laboratory prognostic markers in COVID-19 patients. The aim of our study was to describe the basic clotting parameters in COVID-19 patients and their prognostic role in different clinical forms of the disease. Material and Methods: We enrolled 67 COVID-19 patients admitted to the Emergency Department. A cohort of 67 age- and sex-matched non-COVID-19 patients with acute respiratory illness was used as a control group. For all patients, platelet count (PLT), prothrombin time (PT), activated thromboplastin time (aPTT), C-reactive protein (PCR), fibrinogen, and D-dimer were determined. The COVID-19 population was divided in two groups according to the presence or absence of SARS. The clotting factors values were compared between the groups. Results: At admission, the COVID-19 patients showed statistically significant increased levels of fibrinogen (601.5 (480–747) vs. 455 (352.5–588.5) mg/dL; p = 0.0000064), and a higher percentage of patients had fibrinogen levels >400 mg/dL (86% vs.58%; p = 0.0054) compared to the control group. The levels of fibrinogen were higher in COVID-19 patients with SARS compared to those without SARS (747 (600.0–834.0) vs. 567 (472.5–644.50); p = 0.0003). Conclusion: Fibrinogen seems to increase early in COVID-19 patients and may be used as a risk stratification marker for the early detection of a subgroup of COVID-19 patient at increased risk to develop SARS, who might benefit from a different and thorough clinical surveillance and treatment.
has issue date	2020-05-07(xsd:dateTime)
bibo:doi	10.3390/jcm9051371
bibo:pmid	32392741
has license	cc-by
sha1sum (hex)	d812aa086db71dc1999f37317411cf61040f7ede
schema:url	https://doi.org/10.3390/jcm9051371
resource representing a document's title	Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort
has PubMed Central identifier	PMC7290348
has PubMed identifier	32392741
schema:publication	J Clin Med
resource representing a document's body	covid:d812aa086db71dc1999f37317411cf61040f7ede#body_text
is schema:about of	named entity 'risk stratification' named entity 'patients' named entity 'human' named entity 'patients' named entity 'induce' named entity 'rapidly' named entity 'Clinical Medicine' named entity 'DIVIDED' named entity 'COVID-19' named entity 'FIBRINOGEN LEVELS' named entity 'COUNTRIES' named entity '747' named entity 'EARLY' named entity 'RESULTS' named entity 'KNOWN' named entity 'CONTROL GROUP' named entity 'COVID-19' named entity 'PLT' named entity 'COVID-19' named entity 'Methods' named entity 'prothrombin time' named entity 'The levels' named entity '747' named entity 'compared' named entity 'patients' named entity 'fibrinogen' named entity 'China' named entity 'compared' named entity 'SARS' named entity 'COVID' named entity 'SARS' named entity 'clinical surveillance' named entity 'Fibrinogen' named entity 'platelet count' named entity 'prothrombin time' named entity 'COVID-19' named entity 'Clinical Medicine' named entity 'Italian' named entity 'fibrinogen' named entity 'respiratory illness' named entity 'physical examination' named entity 'clinical practice' named entity 'D-dimer' named entity 'infection' named entity 'COVID' named entity 'hypercoagulable state' named entity 'COVID' named entity 'clinical setting' named entity 'COVID-19' named entity 'hemostasis' named entity 'viral infection' named entity 'severe acute respiratory syndrome' named entity 'inflammatory' named entity 'prothrombin time' named entity 'D-dimer' named entity 'hemostasis' named entity 'DIC' named entity 'China' named entity 'hypercoagulable state' named entity 'COVID' named entity 'lactate dehydrogenase' named entity 'control group' named entity 'thrombin' named entity 'extrinsic pathway' named entity 'C-reactive protein' named entity 'SARS' named entity 'informed consent' named entity 'lung' named entity 'study population' named entity 'COVID' named entity 'microorganisms' named entity 'risk factors' named entity 'hemostasis' named entity 'SARS' named entity 'triage'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software